Home/Supreme Court/Shire Dev., LLC v. Watson Pharm., Inc.

Shire Dev., LLC v. Watson Pharm., Inc.

135 S. Ct. 1174, 191 L. Ed. 2d 130, 83 U.S.L.W. 3625, 2015 U.S. LEXIS 850
CourtSupreme Court of the United States
DecidedJanuary 26, 2015
DocketNo. 14–206.
StatusPublished
Cited by1 cases

This text of 135 S. Ct. 1174 (Shire Dev., LLC v. Watson Pharm., Inc.) is published on Counsel Stack Legal Research, covering Supreme Court of the United States primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Shire Dev., LLC v. Watson Pharm., Inc., 135 S. Ct. 1174, 191 L. Ed. 2d 130, 83 U.S.L.W. 3625, 2015 U.S. LEXIS 850 (U.S. 2015).

Opinion

On petition for writ of certiorari to the United States Court of Appeals for the Federal Circuit. Petition for writ of certiorari granted. Judgment vacated, and case remanded to the United States Court of Appeals for the Federal Circuit for further consideration in light of Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc.,574 U.S. ----, 135 S.Ct. 831, --- L.Ed.2d ---- (2015).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Shire Development, LLC v. Watson Pharmaceuticals, Inc.
787 F.3d 1359 (Federal Circuit, 2015)

Cite This Page — Counsel Stack

Bluebook (online)
135 S. Ct. 1174, 191 L. Ed. 2d 130, 83 U.S.L.W. 3625, 2015 U.S. LEXIS 850, Counsel Stack Legal Research, https://law.counselstack.com/opinion/shire-dev-llc-v-watson-pharm-inc-scotus-2015.